The Current Ratio as of November 2024 (TTM) for 89bio, Inc. (ETNB) is 11.66

According to 89bio, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 11.66. This represents a change of -23.12% compared to the average of 15.16 of the last 4 quarters.

89bio, Inc. (ETNB) Historical Current Ratio (quarterly & annually)

How has ETNB Current Ratio performed in the past?

The mean historical Current Ratio of 89bio, Inc. over the last ten years is 13.63. The current 11.66 Current Ratio has changed 8.45% with respect to the historical average. Over the past ten years (40 quarters), ETNB's Current Ratio was at its highest in in the December 2020 quarter at 25.91. The Current Ratio was at its lowest in in the September 2018 quarter at 0.

89bio, Inc. (ETNB) Current Ratio by Quarter and Year

Discovering the peaks and valleys of 89bio, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

89bio, Inc. (ETNB) Average Current Ratio

How has ETNB Current Ratio performed in the past?

The current Current Ratio of 89bio, Inc. (ETNB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

89bio, Inc. (ETNB) Current Ratio vs. Peers

How is ETNB’s Current Ratio compared to its peers?

89bio, Inc.’s Current Ratio is greater than Madrigal Pharmaceuticals, Inc. (5.98), greater than Pliant Therapeutics, Inc. (10.26), greater than Arcellx, Inc. (4.29), greater than Stoke Therapeutics, Inc. (5.09), less than Day One Biopharmaceuticals, Inc. (14.62), greater than X4 Pharmaceuticals, Inc. (4.89), greater than Inozyme Pharma, Inc. (7.68), greater than Acumen Pharmaceuticals, Inc. (10.43), greater than Mereo BioPharma Group plc (6.10), less than Viking Therapeutics, Inc. (36.47), greater than Intercept Pharmaceuticals, Inc. (4.22), less than Terns Pharmaceuticals, Inc. (32.99), less than Akero Therapeutics, Inc. (17.25), greater than Reata Pharmaceuticals, Inc. (6.75), greater than HOOKIPA Pharma Inc. (3.26), greater than TG Therapeutics, Inc. (4.59), greater than Hepion Pharmaceuticals, Inc. (1.30),

Build a custom stock screener for 89bio, Inc. (ETNB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 89bio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

89bio, Inc. (ETNB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like 89bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.